Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present disclosure relates in general to pirfenidone, a small drug molecule whose chemical name is 5-methyl-l-phenyl-2-(lH)-pyridone. Specifically, the present disclosure relates to a capsule formulation of pirfenidone including pharmaceutically acceptable excipients. Further provided are methods of using such capsule formulation in the treatment of fibrotic conditions and other disorders mediated by cytokines.
• Pirfenidone is a non-peptide synthetic molecule with a molecular weight of
• Pirfenidone 185.23 daltons. Its chemical elements are expressed as C 12 HnNO, and its structure is known.
• the synthesis of pirfenidone has been worked out. Pirfenidone is manufactured and being evaluated clinically as a broad-spectrum anti-fibrotic drug. Pirfenidone has anti-fibrotic properties via: decreased TNF-a expression, decreased PDGF expression, and decreased collagen expression.
• INDs pirfenidone Investigational New Drug Applications
• Phase II human investigations are ongoing or have recently been completed for pulmonary fibrosis, renal glomerulosclerosis, and liver cirrhosis. There have been other Phase II studies that used pirfenidone to treat benign prostate hypertrophy, hypertrophic scarring (keloids), and rheumatoid arthritis.
• Pirfenidone One important use of pirfenidone is known to be providing therapeutic benefits to patients suffering from fibrosis conditions such as Hermansky-Pudlak Syndrome (HPS) associated pulmonary fibrosis and idiopathic pulmonary fibrosis (IPF).
• HPS Hermansky-Pudlak Syndrome
• IPF idiopathic pulmonary fibrosis
• Pirfenidone demonstrates a pharmacologic ability to prevent or remove excessive scar tissue found in fibrosis associated with injured tissues including that of lungs, skin, joints, kidneys, prostate glands, and livers.
• Published and unpublished basic and clinical research suggests that pirfenidone may safely slow or inhibit the progressive enlargement of fibrotic lesions, remove pre-existing fibrotic lesions, and prevent formation of new fibrotic lesions following tissue injuries.
• Pirfenidone is a potent inhibitor of fibrogenic cytokines and TNF-a. It is well documented that pirfenidone inhibits excessive biosynthesis or release of various fibrogenic cytokines such as TGF-Bl, bFGF, PDGF, and EGF. Zhang S et al., Australian and New England Journal Ophthalmology, 26; S74-S76, 1998. Experimental reports also show that pirfenidone blocks the synthesis and release of excessive amounts of TNF-a from macrophages and other cells.
• pirfenidone As an investigational drug, pirfenidone is provided in tablet and capsule forms principally for oral administration. Various formulations have been tested and adopted in clinical trials and other research and experiments. The effectiveness of a formulation may be determined by a plurality of factors, including the amount of pirfenidone it contains, the kinds and relative amounts of pharmacologically acceptable excipients used, and the target patient profile (e.g., the physiological and genetic conditions, disease prognosis, and demographic characteristics of the patient). Changes in these factors cause changes in pharmacokinetic (PK) responses in the patient. Thus, there is a need in general for effective pharmaceutical formulations that elicit desirable pharmacokinetic responses in patients thereby optimizing therapeutic actions of pirfenidone.
• PK pharmacokinetic
• a capsule having a pharmaceutical formulation of 5-methyl-l-phenyl-2-(lH)-pyridone (pirfenidone), which includes 5-30% of pharmaceutically acceptable excipients and 70- 95% of pirfenidone by weight.
• pirfenidone 5-methyl-l-phenyl-2-(lH)-pyridone
• the excipients include disintegrators, binders, fillers, and lubricants.
• disintegrators include agar-agar, algins, calcium carbonate, carboxmethylcellulose, cellulose, clays, colloid silicon dioxide, croscarmellose sodium, crospovidone, gums, magnesium aluminium silicate, methylcellulose, polacrilin potassium, sodium alginate, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone hydroxypropylcellulose, sodium starch glycolate, and starch.
• binders include microcrystalline cellulose, hydroxymethyl cellulose, hydroxypropylcellulose, and polyvinylpyrrolidone.
• fillers include calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, cellulose, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, sorbitol, starch, sucrose, sugar, and xylitol.
• lubricants include agar, calcium stearate, ethyl oleate, ethyl laureate, glycerin, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, magnesium stearate, mannitol, poloxamer, glycols, sodium benzoate, sodium lauryl sulfate, sodium stearyl, sorbitol, stearic acid, talc, and zinc stearate.
• disintegrator 2-30% is binder
• 2-30% is filler
• 0.3-0.8% is lubricant.
• the capsule by weight 2-10% of the capsule is disintegrator, 2-25% is binder, 2-25% is filler, and 0.3-0.8% is lubricant.
• the excipients further include povidone.
• by weight 1-4% of the capsule is povidone.
• the capsule includes 100-400 mg Pirfenidone.
• a method for treating a fibrotic condition comprises administering the aforementioned capsule to a patient suffering from the fibrotic condition.
• fibrotic conditions include pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, keloid, dermal fibrosis, coronary restenosis, and post-surgical adhesions.
• pulmonary fibrosis include idiopathic pulmonary fibrosis and Hermansky-Pudlak Syndromes.
• a method for inhibiting actions of cytokines in a patient suffering from a disorder mediated by such cytokines comprises administering the aforementioned capsule to the patient.
• cytokines include TNF-a, TGF- Bl, bFGF, PDGF, and EGF.
• disorders include multiple sclerosis, arthritis, asthma, chronic rhinitis, and edema.
• the method further comprises administering one or more capsules to the patient one or more times a day, with a total daily intake of pirfenidone greater than 1200 mg.
• the patient is given one or more capsules twice or three times a day.
• a capsule having an effective amount of pirfenidone and pharmaceutically acceptable excipients.
• the capsule when administered in a patient is capable of sustaining a measurable pharmacokinetic response.
• the pharmacokinetic response is characterized by a one or more fold increase in the T max or AUC values than a pirfenidone capsule containing no pharmaceutically acceptable excipients.
• treatment methods of administering such capsules are provided for patients suffering from fibrotic conditions such as idiopathic pulmonary fibrosis and Hermansky- Pudlak Syndrome, and other disorders mediated by cytokines such as TNF-a, TGF- ⁇ l, bFGF, PDGF, and EGF.
• fibrotic conditions such as idiopathic pulmonary fibrosis and Hermansky- Pudlak Syndrome
• cytokines such as TNF-a, TGF- ⁇ l, bFGF, PDGF, and EGF.
• Figure 1 shows changes in the mean serum concentrations of pirfenidone and its metabolite 5-carboxylic acid over time in human subjects included in one of the previously reported pharmacokinetic studies: Shionogi Phase II.
• Figure 2 is a table that shows quantitative compositions of the pirfenidone tablets used in Shionogi Phase II.
• Figure 3 shows changes in pirfenidone serum concentrations over time in human subjects after a single dose of 400 mg pirfenidone delivered orally in capsules without excipients.
• Figure 4 shows changes in pirfenidone serum concentrations over time in human objects following a single dose of 200-300 mg pirfenidone delivered orally in capsules with excipients, according to one embodiment of this disclosure.
• Figure 5 is a table that shows the PK values of the capsules with excipients according to one embodiment of this disclosure, compared to the PK values of capsules without excipients that were used in Schmidt 1974, one of the previously reported PK studies.
• Figure 6 is a table that shows the formulation of pirfenidone/excipient- containing capsules used in the study depicted in Figure 4 and the study depicted in
• Figure 7 is a table that lists the components used to prepare a representative batch of the pirfenidone/excipient formulation of Figure 6.
• Figures 8a-c lists tables that show the stability of the pirfenidone/excipient formulation of Figure 6 at 25°C and 60% relative humidity (Figure 8a), 35°C and 65% relative humidity ( Figure 8b), and 40 0 C and 75% relative humidity (Figure 8c).
• Figures 9a and 9b depict additional representative formulation of pirfenidone/excipient-containing capsules contemplated herein.
• API refers to active pharmaceutical ingredients.
• the API of the capsule and tablet formulations is pirfenidone.
• pharmaceutically acceptable excipients pharmaceutically compatible excipients, and excipients are used interchangeably in this disclosure. They refer to non-API substances such as disintegrators, binders, fillers, and lubricants used in formulating pharmaceutical products. They are generally safe for administering to humans according to established governmental standards, including those promulgated by the United States Food and Drug Administration.
• Disintegrators refer to one or more of agar-agar, algins, calcium carbonate, carboxmethylcellulose, cellulose, clays, colloid silicon dioxide, croscarmellose sodium, crospovidone, gums, magnesium aluminium silicate, methylcellulose, polacrilin potassium, sodium alginate, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone hydroxypropylcellulose, sodium starch glycolate, and starch.
• Binders refer to one or more of microcrystalline cellulose, hydroxymethyl cellulose, hydroxypropylcellulose, and polyvinylpyrrolidone.
• Fillers refer to one or more of calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, cellulose, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, sorbitol, starch, sucrose, sugar, and xylitol.
• Lubricants refer to one or more of agar, calcium stearate, ethyl oleate, ethyl laureate, glycerin, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, magnesium stearate, mannitol, poloxamer, glycols, sodium benzoate, sodium lauryl sulfate, sodium stearyl, sorbitol, stearic acid, talc, and zinc stearate.
• Capsule refers to a generally safe, readily dissolvable enclosure for carrying certain pharmaceutical products. In one embodiment, capsule is made of gelatin. Other suitable matrix substances such as total synthetic polymer chemicals having gelatin-like properties may be used to manufacture pirfenidone capsules according to alternative embodiments of this disclosure.
• AUC refers to the area under the curve that represents changes in blood concentrations of pirfenidone over time.
• C max refers to the maximum value of blood concentration shown on the curve that represents changes in blood concentrations of pirfenidone over time.
• T max refers to the time that it takes for pirfenidone blood concentration to reach the maximum value.
• T 1Z2 refers to the time that it takes for pirfenidone blood concentration to decline to one-half of the maximum level.
• AUC, C ma ⁇ , T max , and T ⁇ 2 are the principle pharmacokinetic parameters that characterize the pharmacokinetic responses of a particular drug product such as pirfenidone in an animal or human subject.
• Schmidt 1974 examined the pharmacokinetics of single dose pirfenidone.
• Pirfenidone was administered orally to 10 healthy adult males at doses of 100, 200, and 400 mg. On day 1, a single dose of 100 mg was given to each subject. On day 3, a single dose of 200 mg was given to each subject. And on day 4, a last single dose of 400 mg was given to each subject. This last single dose of 400 mg was analyzed for pharmacokinetics. Blood plasma samples were collected before dosing and at 0.25, 1, 4, and 6 hr after dosing. Pirfenidone concentrations in plasma were determined by gas chromatography.
• Shionogi Phase II involved serial sampling in a 15-patient subset of a pirfenidone cohort (13 males and 2 females). On day 1 a 200 mg single dose was given to each of the 15 patients, and serum samples were collected before dosing and at 0.5, 1, 2, and 3 hr after dosing. Blood concentrations of pirfenidone were determined by HPLC assay. Figure 1 demonstrates changes in the observed mean serum concentrations of pirfenidone and its metabolite 5-carboxylic acid over time.
• Shionogi Phase II used pirfenidone tablets that included certain pharmaceutically acceptable excipients
• the drug product used in Shionogi Phase II was formulated as compressed, coated tablets of 200 mg of pirfenidone.
• Shionogi Phase II tablets included pharmaceutically acceptable excipients.
• Figure 2 is a table listing the ingredients of the Shionogi Phase II tablets and the quantities of each ingredient. As shown, the core tablet was 285 mg, of which 200 mg was API. Various amounts of disintegrator, filler, binder, and lubricant were included. With the addition of the coating, the total weight of the Shionogi Phase II tablet was 296.4 mg.
• tablet formulations permit generous additions of non-API ingredients including excipients and coating substances, especially high percentage of fillers.
• non-API ingredients may limit the amount of API carried in each tablet.
• capsule formulations tend to facilitate the inclusion of high percentage of API with no or less non-API components.
• Capsules may allow for inclusion of a larger amount of binders, instead of fillers as used more in tablets. Where high percentage of API is desired and specific excipients are not known to be essential, capsule formulations are often adopted.
• this new capsule formulation is capable of eliciting advantageous pharmacokinetic responses in human subjects.
• this new capsule formulation facilitates dissolution and improves flowability in the capsule manufacturing process.
• This capsule formulation includes 100-400 mg pirfenidone.
• One or more pharmaceutically acceptable excipients are added in various embodiments. For example, in one embodiment, by weight 2-10% of the capsule is disintegrator, 2-30% is binder, 2- 30% is filler, and 0.3-0.8% is lubricant.
• the capsule formulation further includes povidone. By weight povidone may constitute 1-4% of the capsule.
• the capsule shell may be made of hard gelatin in one embodiment.
• the shell may be clear or opaque, white or with color in various embodiments.
• the capsule is size 1 in a preferred embodiment. Other sizes may be adopted in alternative embodiments.
• the manufacture of pirfenidone capsules based on the capsule formulation of the various embodiments includes a series of steps. These steps are: preparing pirfenidone granulation, fluid bed drying, milling, lubrication blend, encapsulation, and bulk packaging
• the preparation of pirfenidone granulation may be done in the following sequence. First, povidone is mixed with water and dissolved using an overhead mixer. Second, pirfenidone is milled with croscarmellose and microcrystalline cellulose to break up any lumps. Third, the milled pirfenidone, croscarmellose, and microcrystalline cellulose are added into a high sheer granulator and blended. Fourth, the povidone and water solution is added to the blend. Fifth, the pirfenidone granulation is blended for an additional period of time after the povidone and water solution have been completely added.
• the fluid bed drying process may be preformed on a Fluid Bed Dryer with an inlet temperature of 6O 0 C.
• the milling process may be preformed using a suitable miller such as Quadro Comil ® .
• the lubrication blend process may be conducted with the addition of an appropriate amount of croscarmellose and magnesium stearate.
• the pirfenidone granulation may be further blended at this point.
• the pirfenidone granulation is encapsulated using a suitable encapsulator into two-piece, size 1, gelatin capsules to yield a desired pirfenidone dose of 100-400 mg.
• the dose of 200-300 mg is yielded in a preferred embodiment.
• finished capsules may be packaged in secured, double polybags and stored at controlled room temperature.
• Those skilled in drug research and drug making will appreciate that certain of the aforementioned steps may be modified or omitted, and additional steps may be included, without materially alter the outcome of the manufacturing.
• An exemplary composition of the pirfenidone/excipient formulation- containing capsules that was prepared and tested is provided in Figure 6.
• a representative batch of the pirfenidone/excipient formulation was prepared using routine wet formulation methods to combine the components listed in Figure 7.
• Pharmacokinetic studies were performed on the pirfenidone capsules of the present disclosure.
• a first study depicted in Figure 4 shows average changes in serum concentrations over time in four groups of subjects to whom were administered a single dose of the 267 mg pirfenidone capsule formulation of Figure 6.
• the four lines of tin ' s graph, A, B, C and D represent four different groups of subjects: A, fasted subjects; B * fasted subjects with anatacid administered; C fed subjects; and D fed subjects with anatacid administered.
• FIG. 5 is a table summarizing the resulting PK values for both groups (Capsule Groups I and II), compared to the PK values reported in Schmidt 1974. As demonstrated in Figure 5, T max is significantly longer (an approximately two-fold increase in each of Groups I and II) for these excipient-containing capsules than what was reported in Schmidt 1974.
• AUC is also significantly higher (increased by about two-fold in each of Groups I and II) for these excipient-containing capsules than what was reported in Schmidt 1974. AUC values are computed over a time period of zero to infinity. The values of C max and Ty 2 are also higher than or comparable with those reported in Schmidt.
• PK values especially the increased T max and AUC, indicate a prolonged absorption phase for the pirfenidone capsules with excipients according to the present disclosure. Consequently, these capsules are capable of sustaining prolonged therapeutic actions in a patient. Therefore, compared to the capsules without excipients, as what were used in Schmidt 1974, the capsule formulation with the excipients may be advantageously administered to a patient in need, thereby eliciting desirable pharmacokinetic responses in the patient.
• binders such as microcrystalline cellulose or povidone favorably interact with the amide carbonyl group of pirfenidone forming a transient complex which may then dissociate, resulting in a slow build-up in the plasma concentration of pirfenidone, or a slow decline or clearance in the plasma concentration.
• a simplified dosing regimen e.g., changing from three times a day to twice a day, may be implemented, which is likely to result in greater patient compliance.
• higher C max values suggest that daily dosages may be reduced without altering the therapeutic effects of pirfenidone. A reduced daily dosage may lead to reduction or elimination of toxicity and other adverse effects of the drug.
• these capsules and the formulations also show good stability under various storage conditions over time, hi some embodiments, under various storage conditions the capsules and pirfenidone/excipient formulations provided herein can be stable for at least, or at least about, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 24 months, 36 months, or 48 months.
• the capsules and pirfenidone/excipient formulations provided herein can be stable for at least, or at least about, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 24 months, 36 months, or 48 months.
• the capsules and pirfenidone/excipient formulations provided herein can be stable for at least, or at least about, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 24 months, 36 months, or 48 months, hi another example, under storage conditions of 4O 0 C and 75% relative humidity, the capsules and pirfenidone/excipient formulations provided herein can be stable for at least, or at least about, 3 months, 6 months, 9 months, or 12 months.
• the stability of the capsules and pirfenidone/excipient formulations provided herein is determined by measuring the dissolution rate of the stored capsule and/or pirfenidone/excipient formulations. Any of a variety of dissolution methods provided herein or otherwise known in the art can be performed to determine the stability of capsules and pirfenidone/excipient formulations. Dissolution measurements are in vitro methods known in the art to be representative of in vivo T max and AUC values.
• a dissolution level indicative of an acceptable level of stability is a dissolution of at least, or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, of the pirfenidone in the capsules provided herein.
• dissolution can be determined according to the pharmacopoeial dissolution method specified in USP29.
• the dissolution of the capsule and pirfenidone/excipient formuations at 4O 0 C and 75% relative humidity did not appreciably change over the initial 12 month period.
• One embodiment of this disclosure provides methods for treating fibrotic conditions and other cytokine-mediated disorders. These methods comprise administering the excipients-containing pirfenidone capsules of this disclosure to a patient suffering from a fibrotic condition or a cytokine-mediated disorder.
• the dosing may be twice or three times daily, with one or more capsules per intake.
• the total daily intake is at least 1200 mg pirfenidone.
• the total daily intake amount may vary, depending on the patient profile, including among other things the patient's demographic characteristics, physiological and genetic conditions, and disease prognosis. For example, a child or a senior person may be given a lower amount daily than that given to an ordinary adult.
• pirfenidone The anti-fibrotic activity of pirfenidone is demonstrated in in vivo animal fibrosis models, as well as in vitro cell culture studies with human or animal lung fibroblasts, dermal fibroblasts, and fibroblast-like cells. Those data indicates that pirfenidone may be an effective agent for preventing and treating post-surgical adhesions, myocardial fibrosis, renal fibrosis, liver cirrhosis, atherosclerosis, and other fibrotic disorders.
• TGF- Bl is a potent growth-related peptide whose effects may be observed at femtomolar concentrations. It appears to be ubiquitous, and is a bifunctional regulator of cell proliferation in vitro.
• TGF- Bl enhances extracellular matrix formation by increasing transcription of genes for collagen and fibronectin, decreasing secretion of proteases, increasing secretion of protease inhibitors, and increasing transcription of cellular receptors for matrix proteins.
• pirfenidone may selectively arrest scar enlargement, and remodels or removes scar tissue or fibrosis.
• the dysfunction caused by fibrotic lesion's may be ameliorated by the reduction or removal of the fibrotic lesion following pirfenidone treatment.
• organ and tissue function can be restored, even after the presence of fibrosis for several years.
• pirfenidone When given immediately after an insult, such as trauma, infection, or allergy, to a tissue, pirfenidone also may prevent formation of excessive scar tissue, or fibrotic lesions, and thus help retain normal function and appearance of the tissue.
• Pirfenidone may cause removal of excessive collagenous fibrotic tissue by a phagocytic action of local fibroblasts. This has been observed by examination of histological sections of lung tissue under the light microscope from dogs, mice, rats, and hamsters with pulmonary fibrosis treated with pirfenidone, and also through the electron micrographs of histological sections of lung tissue taken from hamsters with experimentally-induced asbestosis that were treated with pirfenidone. No infiltration of inflammation-inducing neutrophils, PMN cells, monocytes, lymphocytes occurred. [0064] The enhanced proliferation of WB 8 fibroblasts upon in vitro exposure to
• PDGF or bFGF may be blocked by pirfenidone added to cell growth media. Pirfenidone may also inhibit the TGF-Bl induced rise in collagen output in lung and dermal fibroblast cultures.
• the clinical criteria for beneficial response during the first months on pirfenidone included reduction in incidence of coughs, reduction in supplemental oxygen requirements, increased exercise tolerance, reduced dyspnea during exercise, amelioration of cor pulmonale, resumption of normal daily tasks, body weight gain, and survival.
• pulmonary function as gauged by chest x-ray, spirometry, or CO diffusion (DLCO) showed little, if any, change.
• DLCO CO diffusion
• Pirfenidone may induce a remodeling of skin fibrotic lesions to reduce or remove keloids, reduce or remove dermal scars, and remove or lessen the contractures of hypertrophic (post burn injury) scars. In a similar condition, pirfenidone also acts to inhibit postoperative surgical adhesions.
• the capsule formulation of the present disclosure may be administered according to certain embodiments of this disclosure to treat patients suffering from the following disorders:
• Central Nervous System syndromes relapsing-remitting multiple sclerosis, primary and secondary multiple sclerosis, spinal multiple sclerosis, cerebral malaria, viral or bacterial infections of the CNS, bacterial meningitis, "autoimmune" disorders of the central nervous system (CNS), CNS stroke and infarction, brain edema, Parkinson's syndrome, Alzheimer's disease, amylotrophic lateral sclerosis (ALS), and brain concussion or contusion;
• Musculoskeletal syndromes rheumatoid arthritis, trauma-induced arthritis, arthritis caused by a microbial infection, or by a parasite, tendonitis, and, arthritis induced by medical products or drugs (including small synthetic molecules as well as purified natural or synthesized peptides or proteins);
• Pulmonary syndromes acute adult respiratory distress syndrome, asthma, allergic rhinitis, allergic conjunctivitis, chronic obstructive pulmonary disease (COPD), and lung sarcoidosis;
• COPD chronic obstructive pulmonary disease
• Systemic immunologic, inflammatory or toxic syndromes endotoxemia shock syndrome, septic shock, graft-host disease, allograft vasculopathy, hemorrhagic shock, reperfusion injury of the brain or myocardium, thermal burns, radiation injury, general or dermal traumatic or contusion injuries, eosinophilic granuloma, diabetic mellitus (type II), or systemic lupus erythematosus;
• Gastro-intestinal syndromes Crohn's disease, ulcerative colitis, and liver inflammatory disorders; and [0076] 6) Congestive heart failure.
• the capsule formulation of the present disclosure may be administered according to other embodiments to treat patients suffering from the following disorders: pulmonary fibrosis, radiation and drug-induced lung fibrosis, hepatic fibrosis, cardiac fibrosis, keloid, postsurgical adhesions, benign prostate hypertrophy in humans, arteriosclerosis, dermal fibrosis, and coronary restenosis.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Otolaryngology (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Immunology (AREA)
• Vascular Medicine (AREA)
• Gastroenterology & Hepatology (AREA)
• Hematology (AREA)
• Psychiatry (AREA)
• Urology & Nephrology (AREA)
• Hospice & Palliative Care (AREA)
• Pain & Pain Management (AREA)
• Surgery (AREA)
• Diabetes (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (29)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (2)

Family

ID=37898745

Family Applications (1)

Country Status (28)

Cited By (20)

Families Citing this family (30)

Citations (2)

Family Cites Families (31)

• 2005
  • 2005-09-22 NZ NZ591443A patent/NZ591443A/xx unknown
• 2006
  • 2006-09-22 DK DK06815221.4T patent/DK1940364T4/da active
  • 2006-09-22 EP EP06815221.4A patent/EP1940364B2/en active Active
  • 2006-09-22 CA CA2620380A patent/CA2620380C/en active Active
  • 2006-09-22 WO PCT/US2006/037057 patent/WO2007038315A2/en not_active Ceased
  • 2006-09-22 PT PT68152214T patent/PT1940364E/pt unknown
  • 2006-09-22 CN CNA2006800348742A patent/CN101267810A/zh active Pending
  • 2006-09-22 ZA ZA200802237A patent/ZA200802237B/xx unknown
  • 2006-09-22 CU CU20080043A patent/CU20080043A7/es unknown
  • 2006-09-22 KR KR1020087006806A patent/KR20080046673A/ko not_active Ceased
  • 2006-09-22 CN CN2013103433683A patent/CN103393607A/zh active Pending
  • 2006-09-22 AU AU2006295440A patent/AU2006295440B2/en not_active Revoked
  • 2006-09-22 KR KR1020137022095A patent/KR101645069B1/ko active Active
  • 2006-09-22 PL PL06815221.4T patent/PL1940364T5/pl unknown
  • 2006-09-22 SI SI200631819T patent/SI1940364T2/sl unknown
  • 2006-09-22 GE GEAP200610558A patent/GEP20115303B/en unknown
  • 2006-09-22 CN CN201410057564.9A patent/CN103735530A/zh active Pending
  • 2006-09-22 UA UAA200805048A patent/UA99433C2/ru unknown
  • 2006-09-22 US US12/067,712 patent/US7988994B2/en active Active
  • 2006-09-22 NZ NZ565957A patent/NZ565957A/en unknown
  • 2006-09-22 NZ NZ600129A patent/NZ600129A/en unknown
  • 2006-09-22 AP AP2008004390A patent/AP2655A/xx active
  • 2006-09-22 EA EA200800881A patent/EA030093B1/ru active Protection Beyond IP Right Term
  • 2006-09-22 UA UAA201203869A patent/UA115861C2/uk unknown
  • 2006-09-22 ES ES06815221T patent/ES2496144T5/es active Active
  • 2006-09-22 EP EP11007850A patent/EP2431025A1/en not_active Withdrawn
  • 2006-09-22 BR BRPI0616324-6A patent/BRPI0616324A2/pt not_active Application Discontinuation
  • 2006-09-22 MX MX2008003882A patent/MX2008003882A/es active IP Right Grant
  • 2006-09-22 CA CA2762013A patent/CA2762013C/en active Active
  • 2006-09-22 KR KR1020147004496A patent/KR101675651B1/ko active Active
  • 2006-09-22 JP JP2008532431A patent/JP5837732B2/ja active Active
  • 2006-09-22 AP AP2012006231A patent/AP2012006231A0/xx unknown
• 2008
  • 2008-02-04 IL IL189273A patent/IL189273A/en active IP Right Grant
  • 2008-02-12 NO NO20080759A patent/NO345131B1/no unknown
  • 2008-03-19 TN TNP2008000136A patent/TNSN08136A1/en unknown
  • 2008-04-17 MA MA30855A patent/MA29875B1/fr unknown
  • 2008-04-22 EC EC2008008394A patent/ECSP088394A/es unknown
• 2009
  • 2009-04-17 US US12/426,182 patent/US7767225B2/en active Active
• 2011
  • 2011-04-05 AU AU2011201520A patent/AU2011201520B2/en not_active Revoked
  • 2011-06-16 US US13/162,048 patent/US8383150B2/en active Active
• 2012
  • 2012-08-17 JP JP2012180913A patent/JP5715101B2/ja active Active
• 2013
  • 2013-02-25 US US13/776,079 patent/US8753679B2/en active Active
• 2014
  • 2014-05-07 US US14/271,720 patent/US20140242159A1/en not_active Abandoned
  • 2014-06-24 JP JP2014129551A patent/JP2014169341A/ja active Pending
  • 2014-09-10 CY CY20141100731T patent/CY1115544T1/el unknown
• 2015
  • 2015-07-09 IL IL239868A patent/IL239868A0/en unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events